Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) dropped 3.6% on Thursday . The stock traded as low as $6.66 and last traded at $6.75, with a volume of 2,036,609 shares trading hands. The stock had previously closed at $7.00.

FOLD has been the subject of several research analyst reports. Bank of America Corp. initiated coverage on Amicus Therapeutics in a report on Wednesday, May 18th. They issued a “buy” rating and a $10.00 price objective for the company. Leerink Swann restated an “outperform” rating and issued a $17.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, June 1st. Zacks Investment Research upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price objective for the company in a report on Monday, July 25th. Finally, Chardan Capital set a $15.00 price objective on Amicus Therapeutics and gave the company a “buy” rating in a report on Thursday, August 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $12.19.

The stock has a 50 day moving average price of $6.56 and a 200 day moving average price of $6.88. The company’s market cap is $992.13 million.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.07. On average, equities research analysts anticipate that Amicus Therapeutics Inc. will post ($1.35) EPS for the current fiscal year.

In related news, insider Jay Barth sold 20,916 shares of the firm’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $7.00, for a total transaction of $146,412.00. Following the completion of the sale, the insider now directly owns 25,458 shares of the company’s stock, valued at approximately $178,206. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Perceptive Advisors Llc sold 1,100,000 shares of the firm’s stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $6.81, for a total value of $7,491,000.00. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Amicus Therapeutics stock. Jennison Associates LLC raised its position in shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) by 3.3% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 4,123,955 shares of the biopharmaceutical company’s stock after buying an additional 133,138 shares during the period. Jennison Associates LLC owned 3.30% of Amicus Therapeutics worth $40,002,000 at the end of the most recent quarter.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.